Updates in the Treatment of Secondary Acute Myeloid Leukemia

Patients with Philadelphia chromosome–positive CML in chronic phase will no longer be required to fast before taking nilotinib tablets.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Results from the FELIX trial support the approval of obecabtagene autoleucel in B-cell ALL.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Consolidative hematopoietic cell transplantation also confers improved progression-free survival among those with relapsed/refractory B-ALL.

Investigators will present topline data from the phase 2/3 study of uproleselan/chemotherapy at a future medical meeting.